NCT02514967View on ClinicalTrials.gov

CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis

PHASE3TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

February 28, 2017

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

Blisibimod

Administered via subcutaneous injection once per week

DRUG

Placebo

Administered via subcutaneous injection once per week

Trial Locations (3)

0102

Investigator Site 004, Tbilisi

0179

Investigator Site 001, Tbilisi

0186

Investigator Site 002, Tbilisi

Sponsors
All Listed Sponsors
lead

Anthera Pharmaceuticals

INDUSTRY

NCT02514967 - CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis | Biotech Hunter | Biotech Hunter